- Home
- » Tags
- » Bile acid sequestrant
Top View
- Studies on Cholesterol and Bile Acid Metabolism in Relation to Plasma Lipoproteins in Humans
- Clinical Characteristics and Lipid Lowering Treatment of Patients Initiated on Proprotein Convertase Subtilisin- Kexin Type 9 Inhibitors: a Nationwide Cohort Study
- Investigations of 12Α-Hydroxylated Bile Acid Signaling in Intestinal Organoids
- Clinical Criteria, Step Therapy, and Quantity Limits for Tenncare Preferred Drug List (PDL) September 1, 2021
- Gastroesophageal Reflux Disease: a Review
- Review of Management of Pruritus in Palliative Care
- WELCHOL (Colesevelam
- WO 2012/027331 Al 1 March 2012 (01.03.2012) PCT
- Bile Acid Sequestrants in Type 2 Diabetes: Potential Effects on GLP1 Secretion
- Therapeutic Class Overview Bile Acid Sequestrants
- Caresource Prior Authorization Criteria (Updated November, 2019)
- (12) United States Patent (10) Patent No.: US 7417,039 B2 Davis (45) Date of Patent: Aug
- Prescribed Medications and Otcs: Interactions and Timing Issues
- An Alternative Treatment for Bile Acid Diarrhoea
- Appendix A: Medications Used in the Treatment of Inborn Errors
- Bile Acid Sequestrants • Niacin • Fibrates • Mipomersen • Lomitapide • LDL Apheresis Evidence for Treating All FH Patients
- Bile Acid Signaling in Neurodegenerative and Neurological Disorders
- What Are Effective Medication Combinations for Dyslipidemia?
- Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
- Study Protocol: ICP-3718-202-P-03
- Colesevelam Hydrochloride: a Bile Acid Sequestrant for Glycemic Control and Treatment of Dyslipidemia in Type 2 Diabetes Mellitus
- Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome
- Ironwood Investor Day December 12, 2013
- Short Bowel Syndrome in Adults – Part 4A a Guide to Front Line Drugs Used in the Treatment of Short Bowel Syndrome
- Medicare Prior Authorization Requirements
- Hypertension and Hyperlipidemia 2016: What’S New in the Treatment Guidelines
- Classifications of Drugs
- Bile Acid Sequestrants in Type 2 Diabetes: Potential Effects on GLP1 Secretion
- For More Information, Please Contact
- Lipotropics, Other Review 02/05/2008